A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Andrew M EvensBrad S Kahl

Abstract

We sought to improve upon frontline bendamustine/rituximab (BR) induction therapy followed by rituximab maintenance in untreated high-risk follicular lymphoma (FL). Patients were randomized to BR induction followed by 2-year rituximab maintenance (BR-R), BR with bortezomib and rituximab maintenance (BVR-R), or BR followed by lenalidomide (1 year) with rituximab maintenance (BR-LR). Dual primary objectives were complete remission (CR) rate and 1-year disease-free survival (DFS); 289 patients enrolled (NCT01216683). For induction, 92%, 87%, and 86% of patients randomized to BR-R, BVR-R, or BR-LR received six cycles, respectively. CR rate with BR versus BVR induction was 62% versus 75%, respectively (P = 0.04). One-year DFS rates with BR-R versus BR-LR were 85% versus 67%, respectively (P = 0.0009). This was due to an imbalance in CR rates post-BR induction and discontinuation due to adverse events (AEs). The most common grade 3-4 AEs for BVR versus BR were neutropenia and sensory neuropathy (12% vs <1%); 83% of the latter occurred with intravenous bortezomib. The most common grade 3-4 AEs related to LR versus rituximab maintenance were neutropenia 66% versus 21%, respectively (P < 0.0001), and febrile neutropenia 10% versus 2%, r...Continue Reading

References

May 6, 2004·Blood·Philippe Solal-CélignyEmili Montserrat
Dec 23, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andre GoyAlma M Rodriguez
Dec 23, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Owen A O'ConnorAndrew D Zelenetz
Apr 12, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandra J StraussT Andrew Lister
May 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas J SmithAntonio C Wolff
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Apr 11, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael HeroldUNKNOWN East German Study Group Hematology and Oncology Study
Mar 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard HochsterSandra J Horning
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Massimo FedericoPhilippe Solal-Céligny
Oct 7, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas E WitzigJulie M Vose
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Emmanuel BachyGilles Salles
Aug 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nathan FowlerBruce D Cheson
May 7, 2013·Haematologica·Emmanuel BachyUNKNOWN Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Jul 1, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carla CasuloJonathan W Friedberg
Dec 29, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Qian ShiDaniel J Sargent
Oct 5, 2017·The New England Journal of Medicine·Robert MarcusWolfgang Hiddemann
Jun 2, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfgang HiddemannRobert E Marcus
Sep 6, 2018·The New England Journal of Medicine·Franck MorschhauserUNKNOWN RELEVANCE Trial Investigators
Mar 22, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John P LeonardUNKNOWN AUGMENT Trial Investigators

❮ Previous
Next ❯

Citations

Jan 23, 2021·Clinical Lymphoma, Myeloma & Leukemia·Swetha KambhampatiCharalambos B Andreadis
Mar 9, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Stefano FogliRomano Danesi
Jun 10, 2021·Hematological Oncology·Brad Kahl
Jul 2, 2021·Journal of Hematology & Oncology·Walter Hanel, Narendranath Epperla

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.